$IMUX News

Last published 2d ago

2d agoIMUXIMMUNIC, INC. (IMUX) GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - IMMUNIC INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Welcome to Guggenheim's third annual healthcare innovation conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. It is my pleasure to introduce our next p
1w agoIMUXImmunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026PR NewswireNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a
3w agoIMUXImmunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPR Newswire– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared
3w agoIMUXImmunic Appoints Jaa Roberson as Chief People OfficerPR Newswire– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Immunic,
1mo agoIMUXImmunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
2mo agoIMUXImmunic Virtual Relapsing MS RnD Day - IMMUNIC INCEarnings Call TranscriptsAll right, good morning to everyone on our webinar today and welcome to Immunix Virtual R&D Day, focusing on our relapsing MS development program with Vitofluidimus Calcium. My name is Jessica Brue, Vice President Invest
2mo agoIMUXImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026PR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
2mo agoIMUXImmunic Appoints Chitrang Davé as Chief Data and Digital OfficerPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
3mo agoIMUXImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePR Newswire– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial
4mo agoIMUXImmunic to Participate in Investor Conferences in JulyPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
5mo agoIMUXImmunic to Participate in Investor, Industry and Scientific Conferences in JunePR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
5mo agoIMUXImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
5mo agoIMUXImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive OfficerPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
5mo agoIMUXImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
6mo agoIMUXImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
6mo agoIMUXImmunic to Participate in Investor and Medical Conferences in MayPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
6mo agoIMUXImmunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical OfficerPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
6mo agoIMUXImmunic, Inc. Announces 1-for-10 Reverse Stock SplitPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the...
7mo agoIMUXImmunic to Participate in Scientific and Medical Conferences in AprilPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
7mo agoIMUXImmunic Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
7mo agoIMUXImmunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon CongletonPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today...
8mo agoIMUXImmunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
8mo agoIMUXImmunic to Participate in Investor Conferences in MarchPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
8mo agoIMUXImmunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate UpdatePR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
8mo agoIMUXImmunic Announces Closing of Oversubscribed Private Placement FinancingPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
9mo agoIMUXImmunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage CompanyPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
9mo agoIMUXImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
10mo agoIMUXImmunic Highlights 2025 Accomplishments and Upcoming MilestonesPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
11mo agoIMUXImmunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in DecemberPR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
12mo agoIMUXImmunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireImmunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
1y agoIMUXImmunic to Participate in Industry and Investor Conferences in NovemberPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic to Participate in Scientific and Investor Conferences in OctoberPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic to Participate in Investor and Scientific Conferences in SeptemberPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingPR NewswireImmunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small...
1y agoIMUXImmunic to Participate in Investor, Scientific and Industry Conferences in JunePR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingPR NewswireImmunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small...
1y agoIMUXImmunic, Inc. Announces Proposed Public OfferingPR NewswireImmunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small...
1y agoIMUXImmunic to Participate in Scientific and Industry Conferences in MayPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsPR NewswireImmunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small...
1y agoIMUXImmunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsPR NewswireImmunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small...
1y agoIMUXImmunic, Inc. to Participate in Scientific and Industry Conferences in AprilPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic to Participate in Scientific and Investor Conferences in MarchPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple SclerosisPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
1y agoIMUXImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingPR NewswireImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...